Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel ; volume:39 ; number:9 ; day:7 ; month:7 ; year:2021 ; pages:1021-1044 ; date:9.2021
PharmacoEconomics ; 39, Heft 9 (7.7.2021), 1021-1044, 9.2021
- Urheber
-
Facey, Karen M.
Espin, Jaime
Kent, Emma
Link, Angèl
Nicod, Elena
O’Leary, Aisling
Xoxi, Entela
Vijver, Inneke van de
Zaremba, Anna
Benisheva, Tatyana
Vagoras, Andrius
Upadhyaya, Sheela
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-021-01050-5
- URN
-
urn:nbn:de:101:1-2021103110193933912655
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Facey, Karen M.
- Espin, Jaime
- Kent, Emma
- Link, Angèl
- Nicod, Elena
- O’Leary, Aisling
- Xoxi, Entela
- Vijver, Inneke van de
- Zaremba, Anna
- Benisheva, Tatyana
- Vagoras, Andrius
- Upadhyaya, Sheela
- SpringerLink (Online service)
Ähnliche Objekte (12)
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
Managed decline? Muddling through with the sterling (dis)agreements, 1968-74
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Nusinersen (spinale Muskelatrophie) : Nutzenbewertung gemäß § 35a SGB V
Nusinersen (spinale Muskelatrophie) : Addendum zum Auftrag A20-114
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Managed Violence
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
Managed decline? Muddling through with the sterling (dis)agreements, 1968-74
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Nusinersen (spinale Muskelatrophie) : Nutzenbewertung gemäß § 35a SGB V
Nusinersen (spinale Muskelatrophie) : Addendum zum Auftrag A20-114
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
Managed Violence
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries
Managed decline? Muddling through with the sterling (dis)agreements, 1968-74
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
Nusinersen (spinale Muskelatrophie) : Nutzenbewertung gemäß § 35a SGB V
Nusinersen (spinale Muskelatrophie) : Addendum zum Auftrag A20-114
Nusinersen: A Review in 5q Spinal Muscular Atrophy
Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients